title: Is HER2 overexpression sufficient for optimal response to Pertuzumab?
authors.forename: Mehmet Ali Nahit
authors.initials: MA
authors.lastname: Sendur
authors.forename: Sercan
authors.initials: S
authors.lastname: Aksoy
authors.forename: Sebnem
authors.initials: S
authors.lastname: Yaman
authors.forename: Nuriye Yıldırım
authors.initials: NY
authors.lastname: Özdemir
authors.forename: Nurullah
authors.initials: N
authors.lastname: Zengin
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis / Q000037:antagonists & inhibitors*; D020893:Receptor, ErbB-3 / Q000032:analysis
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; D020893:Receptor, ErbB-3; C508053:ERBB2 protein, human; C485206:pertuzumab